Vyome Holdings, Inc. (NASDAQ:HIND) Short Interest Down 27.4% in February

Vyome Holdings, Inc. (NASDAQ:HIND) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 189,139 shares, a decline of 27.4% from the January 29th total of 260,650 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average daily volume of 423,604 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 423,604 shares, the days-to-cover ratio is currently 0.4 days. Approximately 5.0% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e-)” rating on shares of Vyome in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $15.00.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC purchased a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned approximately 0.80% of Vyome as of its most recent filing with the Securities and Exchange Commission (SEC). 22.06% of the stock is owned by institutional investors.

Vyome Price Performance

NASDAQ HIND traded up $0.04 during midday trading on Monday, hitting $3.41. The company had a trading volume of 47,697 shares, compared to its average volume of 277,092. The business has a 50-day moving average of $2.99. Vyome has a twelve month low of $1.75 and a twelve month high of $305.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.